<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467790</url>
  </required_header>
  <id_info>
    <org_study_id>PEX168-Ih</org_study_id>
    <nct_id>NCT02467790</nct_id>
  </id_info>
  <brief_title>Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function</brief_title>
  <official_title>Kinetic Study of Human Pharmacokinetics in Normal Renal Function, and Renal Insufficiency Subject of Polyethylene Glycol Loxenatide (PEX168)(Open, Non-randomized, Parallel-group)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Hansoh Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Hansoh Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare and analysis pharmacokinetics of PEX 168 in patients with renal insufficiency or&#xD;
      normal renal function who were administrated subcutaneously single dose PEX168.To evaluate&#xD;
      dose adjustment of PEX168 administered in patients with renal insufficiency and provide a&#xD;
      scientific basis in patients with renal insufficiency of rational drug use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open, non-randomized, parallel-group, single-dose study that evaluated the&#xD;
      pharmacokinetics of PEX168 when single dose administered with PEX168 in patients with renal&#xD;
      insufficiency and normal renal function subjects. The total duration of each subject's&#xD;
      participation in the study was approximately 45 days, which included up to a 14-day Screening&#xD;
      Period, a 31-day PK sample collecting Period.&#xD;
&#xD;
      Center: This study was conducted at two sites in the Third Xiangya hospital of Center South&#xD;
      University and Shanghai Changhai Hospital.All subjects receives a single 200μg doses of&#xD;
      PEX168 injected subcutaneously on Day 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic index</measure>
    <time_frame>Baseline to Day31</time_frame>
    <description>Prior to administration (within 60 minutes, recorded as 0h) and after administration 24h (Day 2), 48h (Day 3), 72h (day 4), 96h (day 5), 120h (day 6 ), 144h (day 7), 216h (day 10), 312h (day 14 ), 480h (day 21), 648h (day 28), 720h (day 31) collect blood 3 ml and test serum concentrations of PEX168.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and serious adverse events</measure>
    <time_frame>Baseline to Day31</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Mild renal insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEX 168: 200µg,Subcutaneous,one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate renal insufficiency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEX 168: 200µg,Subcutaneous,one time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEX 168: 200µg,Subcutaneous,one time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEX168</intervention_name>
    <description>PEX 168: 200µg,Subcutaneous,one time.</description>
    <arm_group_label>Mild renal insufficiency</arm_group_label>
    <arm_group_label>Moderate renal insufficiency</arm_group_label>
    <arm_group_label>Normal renal function</arm_group_label>
    <other_name>Polyethylene Glycol Loxenatide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 31-65 (both inclusive) years old, male or female;&#xD;
&#xD;
          2. Weight: Male ≥50kg, female ≥45kg, 18≤BMI≤28;&#xD;
&#xD;
          3. The Cockcroft-Gault (CG) formula to estimate creatinine clearance (CLCr), K / DOQI&#xD;
             definition of chronic kidney disease (CKD) 2 patients: 60≤CLcr≤89 ml / min; chronic&#xD;
             kidney disease (CKD) 3 patients: 30≤CLcr≤59 ml / min for renal&#xD;
             insufficiency,Cockcroft-Gault (CG) formula to estimate creatinine clearance (CLCr)&#xD;
             ≥90ml / min for normal subjects.&#xD;
&#xD;
          4. In the 48 hours before the start of the test to the end of the trial period, agreed to&#xD;
             get rid of tobacco, alcohol, caffeine, fruit juice subject;&#xD;
&#xD;
          5. Understand the study procedures and methods, voluntarily participate in this&#xD;
             experiment, and writing and signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected of GLP-1 class of drug allergy or allergy;&#xD;
&#xD;
          2. Before screening,received GLP-1 receptor agonists, GLP-1 analogs, DPP-IV inhibitors or&#xD;
             any other similar structure of the drug treatment;&#xD;
&#xD;
          3. In addition to the induced renal dysfunction disease itself, suffering from any other&#xD;
             organ of acute illness and those with any influence of drugs in vivo study of chronic&#xD;
             diseases;&#xD;
&#xD;
          4. within 6 months prior to screening,having any surgery, including the impact of gastric&#xD;
             emptying of gastrointestinal surgery;&#xD;
&#xD;
          5. Screened within the previous three months to participate in blood donation and blood&#xD;
             donation ≥400mL, or who participate in blood donation or blood transfusion within one&#xD;
             month;&#xD;
&#xD;
          6. Within 3 months before screening participated in any drug or medical device trials are&#xD;
             (including placebo);&#xD;
&#xD;
          7. Drinking, smoking addiction, drug abuse and drug abusers;&#xD;
&#xD;
          8. In addition to judging laboratory abnormalities diagnosis of renal dysfunction caused&#xD;
             by disease, there are other clinically significant laboratory abnormalities (Note:&#xD;
             Patients with moderate to severe anemia (Hb &lt;60g / L), severe hypertension ( SBP&gt;&#xD;
             160mmHg and / or diastolic blood pressure&gt; 100mmHg) patients, heart rate&gt; 100bmp, ECG&#xD;
             QTc&gt; 450ms were required to exclude;&#xD;
&#xD;
          9. ALT&gt; 1.5 times the upper limit of normal and / or aspartate transaminase&gt; 1.5 times&#xD;
             the upper limit of normal and / or total bilirubin&gt; 1.5 times the upper limit of&#xD;
             normal;&#xD;
&#xD;
         10. Fasting triglycerides&gt; 5.64mmol / L (500mg / dl);&#xD;
&#xD;
         11. Beyond the normal range of serum amylase, and the clinical significance is determined&#xD;
             by the investigator;&#xD;
&#xD;
         12. Pancreatitis, pancreatic cancer a history;&#xD;
&#xD;
         13. Blood thyroid stimulating hormone (TSH) beyond the normal range and clinically&#xD;
             significant judgment by the investigator;&#xD;
&#xD;
         14. The pregnancy test was positive women of childbearing age, or pregnant women,&#xD;
             breastfeeding women, and within six months there have been unwilling or unable to take&#xD;
             family planning and effective contraception during the trial of male / female&#xD;
             volunteers;&#xD;
&#xD;
         15. The hepatitis B surface antigen, hepatitis C antibody, HIV antibody, syphilis antibody&#xD;
             test positive;&#xD;
&#xD;
         16. Researchers believe any situation that might lead to any subject can not be completed&#xD;
             or to the subject of this study bring significant risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>31 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoping Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Xiangya Hospital,Center South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hao Zhang, MD</last_name>
    <phone>13975806919</phone>
    <email>zhanghaoliaoqin@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guoping Yang, MD</last_name>
    <phone>13974817168</phone>
    <email>ygp9880@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Third Xiangya Hospital, Central South Univety</name>
      <address>
        <city>Chang Sha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao Zhang, MD</last_name>
      <phone>13975806919</phone>
      <email>zhanghaoliaoqin@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Guoping Yang, MD</last_name>
      <phone>13974817168</phone>
      <email>ygp9880@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>January 23, 2016</last_update_submitted>
  <last_update_submitted_qc>January 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

